Advertisement

Topics

CardioVascular BioTherapeutics Company Profile

06:26 EDT 21st September 2017 | BioPortfolio

CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death. The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1141 a human protein manufactured using a proprietary technology. FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes. CVBT-141A, the Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion) both in patients also receiving coronary by-pass procedures and in patients with severe coronary heat disease (CHD) receiving CVBT-141A, as the sole therapy. Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients. The protocol design for the Phase II trial is underway, with FDA input, and is planned to initiate in 2007. CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1141 aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1.

Location

1635 Village Center Circle
Suite 250
Las Vegas
NV
89134
United States of America

Contact

Phone: (702) 248-1174


News Articles [906 Associated News Articles listed on BioPortfolio]

Lion Biotechnologies changes name to Iovance Biotherapeutics

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies t...

Pfizer starts work on Missouri biotherapeutics R&D hub

Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.

Iovance Biotherapeutics appoints Timothy Morris CFO

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced the appointment of Timothy E. Morris as Chie...

Pierre Fabre Acquires Immunotherapies from Igenica Biotherapeutics

NewsPierre Fabre Pharmaceuticals acquires promising assets from Igenica Biotherapeutics in the field of immuno-oncology.

Agilis Biotherapeutics, Gene Therapy Research Institution partner

Agilis Biotherapeutics, a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), and Gene Therapy Research Institution (GTR...

Biotech Aeglea BioTherapeutics nets $11.7mm through FOPO

Aeglea BioTherapeutics Inc. (enzyme-based therapeutics for rare diseases and cancer) netted $11.7mm through a follow-on public offering of 3mm common shares at $4.10. The company will use the offerin...

Pierre Fabre to buy Igenica Biotherapeutics’ assets for treating cancer patients

French private pharmaceutical group Pierre Fabre has signed a new definitive purchase agreement to acquire several assets from US biotechnology company Igenica Biotherapeutics.

Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Tuesday, September 5th 2017 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline o...

Drugs and Medications [17 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [2066 Associated PubMed Articles listed on BioPortfolio]

TILT Biotherapeutics.

Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.

The need for novel approaches to cardiovascular drug development served as the impetus to convene an open meeting of experts from the pharmaceutical industry and academia to assess the challenges and ...

Cardiovascular Disease in Korean Americans: A Systematic Review.

Despite Korean Americans being one of the fastest growing immigrant groups in the United States, little is known about their cardiovascular health or cardiovascular disease risk factors.

Cardiovascular Effects of Antidiabetic Therapies.

Type 2- diabetes mellitus (T2DM) represents a major risk factor for cardiovascular complications and mortality. Strict glucose control in the early course of the disease prevents cardiovascular compli...

A Systematic Review of Interventions to Improve Health Factors or Behaviors of the Cardiovascular Health of Prisoners During Incarceration.

Prisoners are disproportionately affected by cardiovascular disease and its risk factors. However, primary prevention of cardiovascular disease in correctional settings has been widely neglected, and ...

Clinical Trials [2371 Associated Clinical Trials listed on BioPortfolio]

Factors Influencing Cardiovascular Prognosis

The purpose of this study is to identify risks for cardiovascular events in a follow up period of 10 years.

Work Organization and Cardiovascular Disease

To determine the combined effects of job strain and social isolation on cardiovascular morbidity and mortality.

Role of Vitamin D in Secondary Prevention of Cardiovascular Events

The purpose of this study is to determine if Vitamin D supplementation helps prevent recurrent cardiovascular events, such as heart attack or stroke, in patients who have already experienc...

Partnership Programs for Reducing Cardiovascular Disparities in Native Hawaiians

The purpose of this study is to improve cardiovascular disease (CVD) outcomes in racial and ethnic minorities in Hawaii.

Genetics and Cardiovascular Reactivity in Young Twins

To evaluate the effects of genetic variants in all of the nine adrenergic receptor subtype genes, alone or in combination, on cardiovascular reactivity and other quantitative cardiovascula...

Companies [675 Associated Companies listed on BioPortfolio]

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

CardioVascular BioTherapeutics

CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide le...

Cardiovascular Consultants, Ltd.

Cardiovascular Consultants, Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate ...

Cardiovascular Consultants Ltd.

Cardiovascular Consultants Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate c...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

More Information about "CardioVascular BioTherapeutics" on BioPortfolio

We have published hundreds of CardioVascular BioTherapeutics news stories on BioPortfolio along with dozens of CardioVascular BioTherapeutics Clinical Trials and PubMed Articles about CardioVascular BioTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CardioVascular BioTherapeutics Companies in our database. You can also find out about relevant CardioVascular BioTherapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record